Neuropsychiatric symptoms seen in Alzheimer's disease (AD) are not simply a consequence
of neurodegeneration, but probably result from differential neurotransmitter alterations …

Background It has been hypothesized that alterations of the serotonergic system contribute
to neuropsychiatric symptoms in Alzheimer disease (AD). Cellular expressions of the two …

Mounting evidence accumulated over the past few years indicates that the neurotransmitter
serotonin plays a significant role in cognition. As a drug target, serotonin receptors have …

Behavioral and psychological symptoms of dementia (BPSD) represent common
manifestations among patients affected by Alzheimer's disease (AD). Some reports have …

The behavioral and psychological symptoms of dementia (BPSD) are an area of clinical and
research attention that has grown significantly during the past decade. It is now recognized …

Neuropsychiatric symptoms (NPS) occur in nearly all patients with Alzheimer's Disease
(AD). Most frequently they appear since the mild cognitive impairment (MCI) stage preceding …

Depression and dementia, in particular Alzheimer's disease (AD), are critically important
issues in the mental health of old age. Both conditions apparently reduce quality of life and …

Drugs acting through 5-hydroxytryptamine (serotonin or 5-HT) systems modulate memory
and its alterations, although the mechanisms involved are poorly understood. 5-HT drugs …

Depression and anxiety are highly prevalent in most neurological disorders and can have a
major impact on the patient's disability and quality of life. However, mostly due to the …

Objective Serotoninergic neurotransmission may modulate β‐amyloid peptide (Aβ)
metabolism through upregulation of α‐secretase. Early Parkinson disease (PD) shows …